Skip to main content

Table 2 Baseline characteristics of the patients with RA-ILD

From: Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

 

GAP / ILD-GAP stage I (n = 39/76.5%)

GAP/ILD-GAP stage II (n = 12/23.5%)

P-value

Age (y)

63.4 ± 11.6

71.5 ± 5.5

0.024

Age at death (y)

72.6 ± 9.9

76.6 ± 5.6

0.266

Male sex

16 (41.0)

12 (100.0)

<0.001

UIP pattern

25 (64.1)

6 (50.0)

0.502

Smoking*

 Never

19 (48.7)

1 (9.1)

0.033a

 Ex-smoker

15 (38.5)

7 (63.6)

 Current smoker

5 (12.8)

3 (27.3)

Serology

 Positive RF**

29 (78.4)

11 (91.7)

0.420a

 Positive ANA***

4 (14.3)

2 (22.2)

0.620a

Medications

 Steroids

36 (92.3)

10 (83.3)

0.580a

 MTX

25 (64.1)

4 (33.3)

0.060

 Biological drugs

11 (28.2)

1 (8.3)

0.250a

Lung functions

 FVC % pred

89.8 ± 15.8

72.6 ± 8.5

<0.001

 FEV1 % pred

85.1 ± 16.3

72.3 ± 8.9

0.013

 DLCO % pred

76.8 ± 15.6

52.8 ± 12.7

<0.001

RA duration (y)

15.7 ± 10.6

14.8 ± 14.4

0.808

CPI points

22.4 ± 12.2

42.8 ± 9.3

<0.001

  1. For eight patients there was no lung function data and therefore the GAP / ILD-GAP score could not be calculated
  2. RF rheumatoid factor, ANA antinuclear antibodies, MTX methotrexate, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, % pred percentage of the predicted value, CPI composite physiologic index
  3. *Data missing from one stage II patient
  4. **Data missing from two stage I patients with positive anti-cyclic citrullinated peptide antibodies
  5. ***Data missing from 14 patients (11 stage I, 3 stage II)
  6. aFisher test
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us